Aptevo Therapeutics Q2 EPS $(5.31) Beats $(6.16) Estimate

Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(5.31) per share which beat the analyst consensus estimate of $(6.16) by 13.8 percent. This is a 96.49 percent increase over losses of $(151.20) per share from the same period last year.